StemiRNA Therapeutics — a clinical stage mRNA biopharmaceutical company located in Shanghai, Beijing and Boston — recently announced the appointment of Dr. Jack Hu as CFO.
Dr. Hu brings nearly two decades of experience in healthcare investment research, financial management, and corporate strategy, the firm said.
Dr. Hu started his career in US Pharmaceutical industry and then moved on to Wall Street to cover US biotechnology stocks at Sellside banks, later he also ran book at buyside, the firm added.
Subsequently, he served as the Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare.
At StemiRNA, Dr. Hu, as the new CFO, will oversee finance management and investor relations while providing support to the company's overall strategy planning and corporate development, the firm noted.